Obiettivo
The first product that AURA will launch to the market will be OSCANN, a diagnosis platform that will allow better, faster
and more accurate diagnosis of neurological disorders affecting Europe’s population in general, but specially youngsters
(e.g. ADHD) and elders (e.g. Parkinson). OSCANN allows for the measurement and analysis of ocular and oculocephalic
movements (OM/OCM) and combines the result with data obtained from other sources (clinical histories, medical
explorations, complementary tests and biomarkers) using Artificial Intelligence (AI) techniques to improve significantly the
quality of medical diagnosis in early stages.
Campo scientifico
- natural sciencescomputer and information sciencesartificial intelligence
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesclinical medicinepsychiatry
- medical and health sciencesbasic medicineneurologyparkinson
Programma(i)
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-1-2016-2017
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
28045 MADRID
Spagna
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.